PL438135A1 - Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych - Google Patents

Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Info

Publication number
PL438135A1
PL438135A1 PL438135A PL43813521A PL438135A1 PL 438135 A1 PL438135 A1 PL 438135A1 PL 438135 A PL438135 A PL 438135A PL 43813521 A PL43813521 A PL 43813521A PL 438135 A1 PL438135 A1 PL 438135A1
Authority
PL
Poland
Prior art keywords
glucose
prevention
treatment
autoimmune diseases
methotrexate conjugate
Prior art date
Application number
PL438135A
Other languages
English (en)
Other versions
PL243573B1 (pl
Inventor
Siddarth AGRAWAL
Marta WOŹNIAK
Sebastian MAKUCH
Wiesław Szeja
Gabriela PASTUCH-GAWOŁEK
Monika Krawczyk
Jerzy Wiśniewski
Andrzej Gamian
Piotr ZIÓŁKOWSKI
Grzegorz Mazur
Original Assignee
Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu filed Critical Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu
Priority to PL438135A priority Critical patent/PL243573B1/pl
Priority to PCT/PL2022/050037 priority patent/WO2022260546A1/en
Priority to EP22820644.7A priority patent/EP4351590B1/en
Publication of PL438135A1 publication Critical patent/PL438135A1/pl
Publication of PL243573B1 publication Critical patent/PL243573B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych, w szczególności reumatoidalnego zapalenia stawów lub łuszczycy.
PL438135A 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych PL243573B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych
PCT/PL2022/050037 WO2022260546A1 (en) 2021-06-11 2022-06-13 A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases
EP22820644.7A EP4351590B1 (en) 2021-06-11 2022-06-13 A glucose-methotrexate conjugate for use in preventing or treating autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Publications (2)

Publication Number Publication Date
PL438135A1 true PL438135A1 (pl) 2022-12-12
PL243573B1 PL243573B1 (pl) 2023-09-11

Family

ID=84425365

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438135A PL243573B1 (pl) 2021-06-11 2021-06-11 Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych

Country Status (3)

Country Link
EP (1) EP4351590B1 (pl)
PL (1) PL243573B1 (pl)
WO (1) WO2022260546A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL243572B1 (pl) * 2021-06-11 2023-09-11 Univ Medyczny Im Piastow Slaskich We Wroclawiu Glikokoniugatowa pochodna metotreksatu i glukozy oraz sposób jej otrzymywania i jej zastosowanie w leczeniu i zapobieganiu nowotworom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095464A1 (ja) * 2004-04-02 2005-10-13 Denki Kagaku Kogyo Kabushiki Kaisha ヒアルロン酸－メトトレキサート結合体
PL242529B1 (pl) * 2018-08-20 2023-03-06 Univ Medyczny Im Piastow Slaskich We Wroclawiu Glikokoniugatowa pochodna metotreksatu i glukozy, jej zastosowanie oraz sposób otrzymywania

Also Published As

Publication number Publication date
EP4351590B1 (en) 2025-12-10
EP4351590C0 (en) 2025-12-10
PL243573B1 (pl) 2023-09-11
WO2022260546A1 (en) 2022-12-15
EP4351590A1 (en) 2024-04-17
EP4351590A4 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
WO2020023978A3 (en) Systems and methods for treating memory impairment
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
PL438135A1 (pl) Koniugat metotreksatu i glukozy do zastosowania w zapobieganiu lub leczeniu chorób autoimmunologicznych
PH12022550617A1 (en) Heteroarylamidopyridinol derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of autoimmune disease
BR112022024382A2 (pt) Formas sólidas de pralsetinibe
CR20230121A (es) Tratamiento de la enfermedad de parkinson
CL2023002698A1 (es) Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
MX2024009868A (es) Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
JOP20240060A1 (ar) سلسلة جزيئات متجاورة مشتقة من-tn3 نوعي لـ cd40l للاستخدام في العلاج أو الوقاية من التهاب المفاصل الروماتويدي
JOP20230210A1 (ar) أشكال بلورية من (4s)-42-كلورو-4-إثيل-37-فلورو-53-مثوكسي-23، 5-ديوكسو-41-(ثلاثي فلورومثيل)-23h-6-آزا-3 (4، 1) بيريدينا-1 (1)- تريازولو-2 (1، 2)، 7 (1) ثنائي بنزيناهبتافان-47-كربوكساميد
GEAP202315302A (en) METHOD FOR TREATING TNFα-RELATED DISEASE
BR112023022130A2 (pt) Âncoras cirúrgicas reposicionáveis
MX387444B (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caidas en pacientes con la enfermedad de parkinson
MX2022013607A (es) Derivados de la pirimidina-4(3h)-ona como antagonistas de trpv4.
PL434198A1 (pl) Związki do leczenia lub diagnostyki COVID-19
de Oliveira et al. Prof. Dr. Michel Zerah
WO2019142147A3 (en) Compositions and methods for the depletion of cd134+ cells
PL431978A1 (pl) Zastosowanie prochlorperazyny i/lub jej farmakologicznie dopuszczalnych soli w leczeniu grzybic wywoływanych przez drożdżaki z rodzaju Candida i Saccharomyces
FR3100449B1 (fr) Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
PL445779A1 (pl) Zastosowanie olejku eterycznego z korzeni dziewięćsiłu pospolitego (Carlina vulgaris L.) do profilaktyki zakażeń wirusem SARS-CoV-2 oraz leczenia choroby COVID-19
WO2022253794A9 (en) Compounds for use in a method for treating an autoimmune and inflammatory disease
Grace et al. IRISH HIST